dc.contributor.author | Måløy, Marthe | |
dc.date.accessioned | 2016-10-07T11:32:47Z | |
dc.date.available | 2016-10-07T11:32:47Z | |
dc.date.issued | 2016-09-20 | |
dc.description | Printer-friendly version of the publisher's version, available at <a href=https://www.minervanett.no/immunterapi-ma-tilbys//>minervanett.no</a>. | en_US |
dc.identifier.citation | Minervanett 2016, 20.09.2016 | en_US |
dc.identifier.cristinID | FRIDAID 1389791 | |
dc.identifier.issn | 0805-7842 | |
dc.identifier.issn | 0806-7465 | |
dc.identifier.uri | https://hdl.handle.net/10037/9792 | |
dc.language.iso | nob | en_US |
dc.publisher | Minerva | en_US |
dc.rights.accessRights | openAccess | |
dc.subject | VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762 | en_US |
dc.subject | VDP::Medisinske Fag: 700::Helsefag: 800::Andre helsefag: 829 | en_US |
dc.title | Immunterapi må tilbys til alle | en_US |
dc.type | Chronicle | en_US |
dc.type | Kronikk | en_US |